Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Devinska Nova Ves – page 27

1 098 clinical trials in Devinska Nova Ves, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Devinska Nova Ves at a glance
1 098
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 098 trials in Devinska Nova Ves

Open in trial search

Study on Ruxolitinib and Methoxsalen for Patients with Steroid-Refractory Chronic Graft-versus-Host Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen
  • Sponsor:Medical Center - University Of Freiburg

Dermatomyositis+4

Recruiting

Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:Medical University Of Vienna

Bladder cancer

Recruiting

Study on the Effectiveness of Gemcitabine Hydrochloride for Patients with Low Grade Bladder Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine Hydrochloride
  • Sponsor:Medical University Of Vienna

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Medica Scientia Innovation Research S.L.

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Breast cancer+1

Recruiting

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Devinska Nova Ves

What the registry says about research in the country

01 Cardiovascular Disease Prevention

Innovative research focusing on lipoprotein reduction and its impact on major cardiovascular events in patients with established heart conditions. Clinical trials are evaluating new therapeutic approaches to reduce cardiovascular risks.

  • Cardiovascular Death Prevention
  • Heart Attack Risk Reduction
  • Stroke Prevention Strategies

Studies aim to advance treatment options for patients with elevated cardiovascular risk factors.

02 Atrial Fibrillation Management

Ground-breaking research comparing the effectiveness of novel anticoagulants in preventing stroke and systemic embolism in patients with atrial fibrillation. These trials focus on developing safer treatment options.

  • Stroke Prevention
  • Blood Clot Prevention
  • Bleeding Risk Assessment

Investigations seek to establish superior treatment protocols for managing irregular heartbeat conditions.

03 Atherosclerotic Disease Treatment

Comprehensive studies evaluating innovative medications for both primary and secondary prevention of atherosclerotic cardiovascular disease. Research focuses on reducing major adverse cardiovascular events.

  • Vascular Disease Management
  • Coronary Event Prevention
  • Cardiovascular Risk Reduction

These trials aim to establish new standards in preventing cardiovascular complications in high-risk populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.